Purpose

To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe.

Methods

Data were from two multi-center, retrospective patient chart review studies conducted in the United Kingdom, Germany, Italy, France and Spain: The Endometrial Cancer Health Outcomes-Europe-First-Line (ECHO-EU-1L) study and the ECHO-EU-Second-Line (ECHO-EU-2L) study. ECHO-EU-1L included recurrent/advanced endometrial cancer patients who received first-line systemic therapy between 1/JUN/2016 and 31/MAR/2020 after recurrent/advanced diagnosis. ECHO-EU-2L included patients with recurrent/advanced endometrial cancer who progressed between 1/JUN/2016 and 30/JUN/2019 following prior first-line systemic therapy. Data collected included patient demographics, MSI/MMR tumor testing and results, and clinical/treatment characteristics.

Results

ECHO-EU-1L included 242 first-line patients and ECHO-EU-2L included 475 s-line patients. For all patients, median age at recurrent/advanced diagnosis was 69 years, roughly half had endometrioid carcinoma histology and over 75% had Stage IIIB-IV disease at initial diagnosis. The prevalence of MSI/MMR testing in the first-line and second-line cohorts was similar (36.4 and 34.9%, respectively). Among those tested, a majority had non-MSI-high/MMR proficient tumors (80.7 and 74.7% among first- and second-line patients, respectively). About 15% had MSI-high/MMR deficient tumors in both cohorts, and a few patients had discordant results (3.4 and 10.8% among first- and second-line patients, respectively).

Conclusion

Prior to the approvals of biomarker-directed therapies for recurrent/advanced endometrial cancer patients in Europe, there were low MSI/MMR testing rates for these patients of just over one-third. Given the availability of biomarker-directed therapies, increased MSI/MMR testing may help inform treatment decisions for recurrent/advanced endometrial cancer patients in Europe.

中文翻译：

---

欧洲晚期子宫内膜癌女性微卫星不稳定性测试的真实患病率及相关状况

目的

旨在评估欧洲复发/晚期子宫内膜癌患者中微卫星不稳定性 (MSI)/错配修复 (MMR) 测试和相关肿瘤状态的现实患病率。

方法

数据来自在英国、德国、意大利、法国和西班牙进行的两项多中心、回顾性患者图表审查研究：子宫内膜癌健康结果-欧洲一线 (ECHO-EU-1L) 研究和 ECHO-欧盟二线 (ECHO-EU-2L) 研究。 ECHO-EU-1L 包括在复发/晚期诊断后于 2016 年 6 月 1 日至 2020 年 3 月 31 日期间接受一线全身治疗的复发/晚期子宫内膜癌患者。 ECHO-EU-2L 包括在先前一线全身治疗后于 2016 年 6 月 1 日至 2019 年 6 月 30 日期间病情进展的复发/晚期子宫内膜癌患者。收集的数据包括患者人口统计、MSI/MMR 肿瘤检测和结果以及临床/治疗特征。

结果

ECHO-EU-1L 包括 242 名一线患者，ECHO-EU-2L 包括 475 名 s 线患者。对于所有患者，复发/晚期诊断时的中位年龄为 69 岁，大约一半的患者在组织学上患有子宫内膜样癌，超过 75% 的患者在初次诊断时患有 IIIB-IV 期疾病。一线和二线队列中 MSI/MMR 检测的发生率相似（分别为 36.4% 和 34.9%）。在接受测试的患者中，大多数患有非 MSI 高/MMR 充分的肿瘤（一线和二线患者中分别为 80.7% 和 74.7%）。两个队列中约有 15% 的患者患有 MSI 高/MMR 缺陷肿瘤，少数患者的结果不一致（一线和二线患者中分别为 3.4% 和 10.8%）。

结论

在欧洲批准针对复发/晚期子宫内膜癌患者的生物标志物导向疗法之前，这些患者的 MSI/MMR 检测率较低，仅略高于三分之一。鉴于生物标志物导向疗法的可用性，增加 MSI/MMR 检测可能有助于为欧洲复发/晚期子宫内膜癌患者的治疗决策提供信息。